综合「中心-辐射」神经科诊疗模式下非创伤性颅内出血诊断后死亡率:辐射中心就诊非劣于中心就诊
该回顾性研究纳入2011年1月1日至2020年9月30日Kaiser Permanente北加州21个医疗中心的成人非创伤性颅内出血患者6978例,其中6170例(88%)首诊于辐射中心。主要终点为90天死亡率,采用分层logistic回归调整ICH评分成分、合并症和人口学特征,非劣效界值定义为OR的95%CI上限≤1.24。结果显示,辐射中心与中心首诊的未调整90天死亡率分别为32.2%和32.7%,调整后OR 1.21(95%CI 0.84-1.74),既未达到非劣效也未达到劣效;排除入住普通病房或随访期间缺乏连续保险的患者后,敏感性分析结果趋近非劣效(OR 0.99,95%CI 0.69-1.44)。作者认为,该发现可能支持「中心-辐射」模式对非创伤性颅内出血患者的安全性和效率,但需进一步研究。
要点
- 在「中心-辐射」神经科诊疗模式中,非创伤性颅内出血患者首诊于辐射中心与中心的未调整90天死亡率分别为32.2%和32.7%。
- 调整ICH评分成分、合并症和人口学特征后,辐射中心首诊的90天死亡风险OR为1.21(95%CI 0.84-1.74),既未达到非劣效(预设OR上限≤1.24)也未达到劣效。
- 敏感性分析排除入住普通病房或随访期间缺乏连续保险的患者后,OR为0.99(95%CI 0.69-1.44),结果趋近非劣效。
- 辐射中心可通过远程会诊(包括影像复核)获得中心神经外科或神经重症专家的支持。
- 作者认为该发现可能支持「中心-辐射」模式对非创伤性颅内出血患者的安全性和效率,但需进一步研究。
适用人群与场景
- 2011年1月1日至2020年9月30日期间在Kaiser Permanente北加州21个医疗中心就诊的成人非创伤性颅内出血患者。
- 其中2个中心为神经科「中心」,19个中心为转诊「辐射中心」;辐射中心可接受中心神经外科或神经重症专家的远程会诊(包括影像复核)。
研究设计与关键结果
- 研究类型:回顾性研究;样本量:6978例;中心数:21个医疗中心(2个中心、19个辐射中心);人群:成人非创伤性颅内出血患者;暴露:首诊于辐射中心 vs 首诊于中心。
- 主要终点:90天死亡率;辐射中心首诊6170例(88%),中心首诊808例(12%)。
- 未调整90天死亡率:辐射中心32.2% vs 中心32.7%。
- 调整后分析:首诊于辐射中心 vs 中心的90天死亡风险OR 1.21(95%CI 0.84-1.74),既未达到非劣效(预设OR上限≤1.24)也未达到劣效。
- 敏感性分析排除入住普通病房或随访期间缺乏连续保险的患者后:OR 0.99(95%CI 0.69-1.44),结果趋近非劣效。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该发现可能支持「中心-辐射」模式对非创伤性颅内出血患者的安全性和效率,但需进一步研究。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Practice guidelines recommend that patients with intracerebral hemorrhage (ICH) be treated in units with acute neuroscience care experience. However, most hospitals in the United States lack this degree of specialization. We sought to examine outcome differences for patients with nontraumatic ICH presenting to centers with and without advanced neuroscience care specialization.
METHODS: This was a retrospective study of adult patients presenting with nontraumatic ICH between 1/1/2011 and 9/30/2020 across 21 medical centers within Kaiser Permanente Northern California, an integrated care system that employs a "hub-and-spoke" model of neuroscience care in which two centers service as neuroscience "hubs" and the remaining 19 centers service as referral "spokes." Patients presenting to spokes can receive remote consultation (including image review) by neurosurgical or neurointensive care specialists located at hubs. The primary outcome was 90-day mortality. We used hierarchical logistic regression, adjusting for ICH score components, comorbidities, and demographics, to test a hypothesis that initial presentation to a spoke medical center was noninferior to hub presentation [defined as an odds ratio (OR) with an upper 95% confidence interval (CI) limit of 1.24 or less].
RESULTS: A total of 6978 patients were included, with 6170 (88%) initially presenting to spoke medical centers. The unadjusted 90-day mortality for patients initially presenting to spoke versus hub medical centers was 32.2% and 32.7%, respectively. In adjusted analysis, presentation to a spoke medical center was neither noninferior nor inferior for 90-day mortality risk (OR 1.21, 95% CI 0.84-1.74). Sensitivity analysis excluding patients admitted to general wards or lacking continuous health plan insurance during the follow-up period trended closer to a noninferior result (OR 0.99, 95% CI 0.69-1.44).
CONCLUSIONS: Within an integrated "hub-and-spoke" neuroscience care model, the risk of 90-day mortality following initial presentation with nontraumatic ICH to a spoke medical center was not conclusively noninferior compared with initial presentation to a hub medical center. However, there was also no indication that care for selected patients with nontraumatic ICH within medical centers lacking advanced neuroscience specialization resulted in significantly inferior outcomes. This finding may support the safety and efficiency of a "hub-and-spoke" care model for patients with nontraumatic ICH, although additional investigations are warranted.
参考来源
- Mark DG, Huang J, Sonne DC, et al. Mortality Following Diagnosis of Nontraumatic Intracerebral Hemorrhage Within an Integrated "Hub-and-Spoke" Neuroscience Care Model: Is Spoke Presentation Noninferior to Hub Presentation? Neurocrit Care. 2023. PMID: 36600074. doi:10.1007/s12028-022-01667-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。